Overview

Spondylitis Trial of Apremilast for Better Rheumatic Therapy

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effectiveness of apremilast in AS as measured by improvement in patients' signs and symptoms of the disease and changes in imaging. Additionally the safety and tolerability of apremilast in AS will be assessed.
Phase:
Phase 2
Details
Lead Sponsor:
Imperial College London
Collaborator:
Celgene Corporation
Treatments:
Apremilast
Thalidomide